ALK and lung cancer: On the one hand, randomised studies with Pemetrexed-containing combinations [33,34,35] showed disappointing results; on the other hand, studies using Paclitaxel and Bevacizumab [24,36] consistently showed therapeutic efficacy, especially in patients with brain metastases, PDL1 ≥ 1%, and/or ALK translocated lung cancers.